As part of the “Xplore-I” clinical study, a bioabsorbable pulmonary valve was successfully implanted in three pediatric patients. The implant from the medical technology company Xeltis is first grown through with the body’s own tissue and then absorbed by the body. What remains is a new, healthy heart valve. The children were in good health and were able to leave the hospital. The clinical feasibility study “Xplore-I” is being conducted at various leading heart centers in Europe under the direction of the study physician Prof. Thierry Carrel.
Xeltis developed from a spin-off of the University of Zurich into one of the world’s most promising medical technology companies. Its cardiovascular implants are made of bioabsorbable polymers, a technology based on a Nobel Prize-winning science. Life Science Communication supports Xeltis with strategy consulting and media relations.
